Biomarker: PD-L1

Histology type: endometrial serous carcinomas

Country: USA

Region: TX

Followed up time :

Subgroup 1 name : positive

Subgroup 1 number: 17

Subgroup 2 name: negative

Subgroup 2 number: 82

Conclusion: In conclusion, PD-L1, TIM-3 and B7-H3 may be potential therapeutic targets in selected patients with ESC. Further investigation of their roles as predictive biomarkers is needed.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : expression

Expression elevation: For all three immune checkpoint markers, cutoff scores of ≥1% for TPS and ≥1 for CPS were used to define positivity, and additional cutoffs (10, 20, and 50) were used to further analyze the significance of immune checkpoint expression.

Statictics: Median;Range

Cohort age: 64 (49–83)

Funtion Uniprot: Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).4 Publications The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

UniProt ID: Q9NZQ7

UniProt Link: https://www.uniprot.org/uniprotkb/Q9NZQ7/entry

Biological function from UniProt: #Adaptive immunity #Immunity

Molecular function from UniProt:

Tissue specificity from UniProt: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

Subcellular UniProt: #Cell membrane #Endosome #Membrane

Alternative name from UniProt:

Recommended name: Programmed cell death 1 ligand 1

Gene name from HGNC: CD274 (B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1)

CD antigen name: CD274

HPA class: Cancer-related genes CD markers Disease related genes FDA approved drug targets

AlphaFold DB: Q9NZQ7

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q9NZQ7

Induction: Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking.

HPA link: https://www.proteinatlas.org/ENSG00000120217-CD274

Tissue specificity RNA from HPA: Tissue enhanced (lung)

Tissue expression from HPA: High expression in placental trophoblasts.

Single cell type specificity Group enriched (Langerhans cells, Syncytiotrophoblasts, granulocytes, Extravillous trophoblasts)

Immune cell specificity: Immune cell enhanced (basophil)

Subcellular summary HPA Localized to the Plasma membrane, Actin filaments In addition localized to the Nucleoplasm

Cancer prognostic summary HPA Prognostic marker in colorectal cancer (favorable) and breast cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology/endometrial+cancer

Survival figure legend: Survival analysis and correlation with PD-L1 expression.

Survival curve link: https://ars.els-cdn.com/content/image/1-s2.0-S0893395222055077-gr5_lrg.jpg

Disease: No disease ID

Note1: Truncation of the 3'-untranslated (3'-UTR) region of CD274 transcripts leads to elevated expression of CD274 in multiple cancers including T-cell leukemia, diffuse large B-cell lymphoma and stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region is caused by structural variants that stabilize CD274 transcripts, leading to overexpression (PubMed:27281199). Increased expression in tumors promotes immune evasion and tumor cell growth by allowing malignant cells to escape destruction by the immune system (PubMed:27281199)

OMIM: 605402

OMIM link2: https://www.omim.org/entry/605402

HGNC ID: HGNC:17635

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635